glp-1 receptor agonists in pediatric and adolescent obesity Oral GLP-1-Based Therapeutics the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, Emerging Strategies Oral GLP-1 Receptor Agonist for
Description
Its prevalence is increasing worldwide, and, like obesity, it affects progressively younger populations compared to the past, with potentially greater impact on chronic complications

Dual GLP-1/GIP Agonists: Expanding Incretin-Based Therapy The Role of GIP in Metabolic Regulation Glucose-dependent insulinotropic polypeptide (GIP) is another incretin hormone secreted by K cells in the small intestine in response to food intake

Some lean mass loss can occur during weight loss regardless of the method used

other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies

Balch B

Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels
